Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Modest Efficacy Outcomes Necessitate Broader Clinical Considerations for Later-Line Treatment Selection in Refractory CRC

November 26th 2025

Tiago Biachi, MD, PhD, reviews how data from the CORRECT, SUNLIGHT, and FRESCO trials inform later-line treatment selection in refractory mCRC.

T-DM1 Displays a Lower Cardiotoxicity Risk vs Other HER2-Targeted Regimens in HER2+ Breast Cancer

November 26th 2025

T-DM1 showed the lowest LVEF decline vs other HER2-targeted regimens, underscoring key differences in cardiac safety.

Cevostamab-Based Combos Could Represent Next Bispecific Antibody Approach in R/R Myeloma

November 25th 2025

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

November 25th 2025

Daniel Spratt, MD, discusses key updates to the National Comprehensive Cancer Network Guidelines for prostate cancer.

European Commission Approves Liso-Cel for R/R Mantle Cell Lymphoma

November 25th 2025

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC

November 25th 2025

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

Dr Raab on Safety and Infection Prophylaxis With Daratumumab-Based Induction Regimens in Myeloma

November 25th 2025

Marc S. Raab, MD, outlines the safety profile of teclistamab plus Dara-VRd in newly diagnosed multiple myeloma from the MajesTEC-5 trial.

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

November 24th 2025

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.

FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer After Prior Enfortumab Vedotin

November 24th 2025

The FDA granted fast track designation to AVZO-103 for urothelial cancer previously treated with enfortumab vedotin.

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

November 24th 2025

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Sacituzumab Tirumotecan Plus Pembrolizumab Improves PFS in PD-L1+ Advanced NSCLC

November 24th 2025

Sacituzumab tirumotecan plus pembrolizumab improved PFS as first-line treatment in PD-L1–positive advanced NSCLC.

Patient Factors Drive Chemotherapy Decision-Making in Metastatic Pancreatic Cancer

November 24th 2025

Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.

Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma

November 20th 2025

Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.

Dr Gonzalez-Martin on the Rationale for Targeting NaPi2b in Ovarian Cancer

November 19th 2025

Antonio Gonzalez-Martin, MD, discusses the rationale for targeting NaPi2b in ovarian cancer.

FDA Grants Accelerated Approval to Sevabertinib in HER2-Mutated Nonsquamous NSCLC

November 19th 2025

The FDA approved sevabertinib for previously treated, nonsquamous non–small cell lung cancer with HER2 TKD activating mutations.

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

November 19th 2025

Justin Taylor, MD discusses how patients use AI to seek cancer information, its accuracy and limitations, and the implications for hematologic malignancy care.

Dr Taylor on Assessing ChatGPT's Ability to Offer Specific Information in Hematologic Malignancies

November 19th 2025

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Genomic, Immune, Epigenetic Features Drive Treatment Decision-Making in High-Risk NSCLC Subtypes

November 19th 2025

Benjamin Herzberg, MD discusses challenges and evolving strategies for managing high-risk NSCLC subsets, underscoring the value of genomic testing.

Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma

November 18th 2025

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

Dr Masserelli on the Clinical Presentation and Management of LEMS in SCLC

November 18th 2025

Erminia Massarelli, MD, PhD, MS, discusses the clinical presentation and management of Lambert–Eaton myasthenic syndrome in the context of small cell lung cancer.